A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

Inclusion Criteria:

   - Diagnosis of multiple sclerosis, in accordance with the revised McDonald criteria
   (2010)

   - At least 2 documented clinical attacks within the last 2 years prior to screening or
   one clinical attack in the years prior to screening (but not within 30 days prior to
   screening)

   - Neurologic stability for greater than or equal to (>/=) 30 days prior to both
   screening and baseline

   - Expanded Disability Status Scale (EDSS) score 0 to 5.5 inclusive

Exclusion Criteria:

   - Primary progressive multiple sclerosis

   - Disease duration of more than 10 years in patients with EDSS score less than or equal
   to (
   - Contraindications for MRI

   - Known presence of other neurological disorders which may mimic multiple sclerosis

   - Pregnancy or lactation

   - Requirement for chronic treatment with systemic corticosteroids or immunosuppressants
   during the course of the study

   - History of or currently active primary or secondary immunodeficiency

   - History of severe allergic or anaphylactic reactions to humanized or murine monoclonal
   antibodies

   - Active infection, or history of or known presence of recurrent or chronic infection
   (for example, hepatitis B or C, Human Immunodeficiency Virus [HIV], syphilis,
   tuberculosis)

   - History of progressive multifocal leukoencephalopathy

   - Contraindications to or intolerance of oral or IV corticosteroids

   - Contraindications to Rebif or incompatibility with Rebif use